Orion - Company Announcement

700,000 Orion A-shares converted into B-shares

ORION CORPORATION        STOCK EXCHANGE RELEASE 19 APRIL 2013 at 09.20 a.m. EEST



In accordance with Section 3 of the Articles of Association of Orion
Corporation, 700,000 A-shares have been converted into 700,000  B-shares. The
conversion has been entered into the Trade Register on 19 April 2013.

The total number of shares in Orion Corporation is 141,257,828  which, after the
conversion, consists of 42,535,318 A-shares and  98,722,510 B-shares.



Orion Corporation





Olli Huotari               Jari Karlson
SVP, Corporate Functions   CFO






Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1694382]